Irwin has just returned from the 9th International Congress of Spondyloarthropathies in Ghent, Belgium.
He was there listening to researchers and academics present and debate current research in spondyloarthritis and heard more about the research into treatments specifically developed for psoriatic arthritis. These are treatments are targeting the IL23/IL17 pathway of the immune system, rather than the TNF pathway.
In the future there could well be more effective treatments for patients with psoriatic arthritis who don't prove receptive to TNF inhibitor therapy.
You can read his blog post for more details.